Tarsus Pharmaceuticals, Inc.
NASDAQTarsus Pharmaceuticals heads into its August 12 earnings release carrying a 14% gain on the week, a short base that has been quietly building for a month, and an options market that has just turned meaningfully less defensive. The most striking setup this week is the divergence between price momentum and short positioning. TARS has gained 19% over the past month, closing at $69.46…
Snapshot as of 20 Sept 2026
Tarsus Pharmaceuticals heads into its August 12 earnings release carrying a 14% gain on the week, a short base that has been quietly building for a month, and an options market that has just turned meaningfully less…
Tarsus Pharmaceuticals is having its best week in months, with the stock up 12% to $70.55 — and the more interesting question is whether the options market's retreat from caution reflects genuine conviction or simply…
Tarsus Pharmaceuticals enters July with a notable divergence: options traders have swung sharply toward calls just as short sellers trim positions modestly — a combination that places the stock in an unusually…
Tarsus Pharmaceuticals just handed bears a difficult week, reporting Q1 results that cleared consensus by a wide margin — and doing so into a short interest position that has already been steadily unwinding. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TARS — free to start on ORTEX.
Sign up for free →Open TARS on ORTEX